The Filing Desk

Axsome Therapeutics vs Ultragenyx Pharmaceutical

Axsome Therapeutics AXSM · Ultragenyx Pharmaceutical RARE · Pharmaceuticals

Ultragenyx Pharmaceutical reported revenue of $673 million in fiscal 2025, about the same as Axsome Therapeutics' $638 million in fiscal 2025. Axsome Therapeutics' revenue grew 65.5% in its latest year, and Ultragenyx Pharmaceutical's grew 20.2%. Axsome Therapeutics had an operating margin of -26.1%, against -79.5% at Ultragenyx Pharmaceutical. Free cash flow was −$94 million at Axsome Therapeutics and −$472 million at Ultragenyx Pharmaceutical.

Side by side

Axsome TherapeuticsUltragenyx Pharmaceutical
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$638M$673M
Revenue growth65.5%20.2%
Revenue growth a year, last 5 years—20.0%
Gross margin——
Operating margin−26.1%−79.5%
Net margin−28.7%−85.4%
Free cash flow−$94M−$472M
Free cash flow margin−14.7%−70.1%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count3.8%8.9%
Last close$135.68$17.22
P/E at the last close——
Insider trades, last 12 monthssold $112.5 millionsold $3.7 million
Piotroski F-score4 of 8—
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Axsome TherapeuticsUltragenyx Pharmaceutical
Operating margin
Percent of revenue
Axsome TherapeuticsUltragenyx Pharmaceutical
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Axsome TherapeuticsUltragenyx Pharmaceutical

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Axsome Therapeutics and Ultragenyx Pharmaceutical pages.